Stepwise Approach for Acute Right Heart Failure
The management of acute right heart failure follows a systematic approach: (1) identify and treat the underlying cause, (2) optimize preload through careful volume assessment and diuresis if congested, (3) reduce RV afterload with selective pulmonary vasodilators, (4) augment contractility with inotropes, and (5) escalate to mechanical circulatory support for refractory cases 1, 2.
Step 1: Identify and Treat the Underlying Cause
The primary management strategy is identifying the etiology—acute pulmonary embolism, RV infarction, acute decompensation of pulmonary arterial hypertension, ARDS, or postcardiotomy shock 1, 3. Transfer to an expert center with ICU admission is warranted for severe cases 4.
Step 2: Preload Optimization
Volume assessment is critical because the RV has a narrow therapeutic window—both hypovolemia and volume overload worsen hemodynamics 5.
If congested (elevated jugular venous pressure, peripheral edema, hepatomegaly): Loop diuretics are Class I recommendation for symptomatic relief and optimization of RV performance 2. Serial kidney function monitoring is essential as patients risk acute kidney injury from both under- and overdiuresis.
If volume status is unclear or hemodynamically unstable: Obtain invasive hemodynamics (RAP, RAP/PAWP ratio) 2. Studies show 70-80% of patients have concordant RAP and PAWP, but isolated RHF presents with high RAP and low/normal PAWP—in this scenario, diuresis is both safe and beneficial 2.
For diuretic resistance (20-50% of patients): Combine loop and thiazide diuretics to increase sodium excretion 2. If persistent congestion with worsening renal dysfunction occurs, escalate to ultrafiltration 2.
In RV infarction with relative volume depletion: Cautious fluid administration may be necessary to maintain adequate RV filling and stroke volume 2. Use echocardiographic guidance to optimize fluid administration 5.
Step 3: Afterload Reduction with Pulmonary Vasodilators
Pulmonary vasodilators lower PVR and PA pressure, improving RV mechanics 2.
Inhaled Options (Preferred for Pulmonary Selectivity):
Inhaled nitric oxide (iNO): Use 10 ppm—exceeding this dose provides no additional PVR reduction and increases risk of methemoglobinemia and bleeding 2. Wean carefully to avoid rebound pulmonary hypertension 2. Disadvantages include high cost and specialized delivery system 2.
Inhaled epoprostenol: Recognized as a reasonable alternative to iNO, particularly when iNO is unavailable or cost-prohibitive 2. Requires specialized delivery system.
Intravenous Options:
IV epoprostenol: Preferred for severe RV failure in PAH due to potency, rapid onset (3-6 minute half-life), and ability to titrate rapidly 2. Doses range 5-120 ng/kg/min, but adverse effects include hypotension, flushing, jaw pain, nausea, and diarrhea 2.
Combination therapies including a prostacyclin analogue: Particularly effective for patients where RHF is the initial manifestation of PAH 2.
Step 4: Contractility Support with Inotropes
Increase contractility and reduce systemic afterload with inodilators 5:
Step 5: Airway and Ventilator Management
Sedation, intubation, and positive-pressure ventilation may reduce preload and precipitate hemodynamic collapse 5.
When possible, use noninvasive respiratory support to optimize oxygenation/ventilation and avoid intubation 5.
If mechanical ventilation is required:
In ARDS with acute cor pulmonale: Use RV-protective ventilation strategy limiting excessive plateau and driving pressures, avoiding severe hypercapnia/hypoxemia, and carefully titrating PEEP to prevent excessive PVR increases 5.
Step 6: Mechanical Circulatory Support for Refractory Cases
For severe or end-stage dysfunction unresponsive to medical management, escalate to mechanical circulatory support 7, 6:
- Options include Impella RP, ProtekDuo, VA-ECMO, or right ventricular assist devices 6, 8
- Balloon atrial septostomy serves as a bridge to definitive therapy in PAH patients, offering decompression of the right atrium and ventricle 8
Critical Pitfalls to Avoid
Overdiuresis: May lead to hypotension and renal dysfunction, especially in low-output RHF 2. Weigh competing interests of decongestion versus perfusion.
Excessive positive-pressure ventilation: Increases RV afterload and reduces preload, potentially causing cardiovascular collapse 5.
IV vasodilators without pulmonary selectivity: Cause systemic hypotension and ventilation/perfusion mismatch 2. Prioritize inhaled agents when possible.
Delayed recognition: RVF is often underrecognized due to heterogeneous presentation 9. Use point-of-care ultrasound and invasive hemodynamics for early identification 9.